We appreciate the engagement from Koehler and Maurer on our Clinical Outlook (Abel, M. L. et al. Ominous-appearing serosal findings on PSMA imaging might belie indolent clinical course. Nat. Rev. Urol. 23, 353–354; 2026)1 and share their cautious perspective that molecular imaging such as prostate-specific membrane antigen (PSMA) PET should complement other clinical data and not alone drive treatment determination (Koehler, D. & Maurer, T.
Esther Mena
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Esther
Contact Esther, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack